Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a ...

Eli Lilly and Eisai's battle to secure NHS reimbursement for their Alzheimer's disease therapies is dragging on, with ...

After a strong start to the year, the value of biotech financings has tailed off a little, but March has seen a clutch of $50 ...

Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey, and this year’s theme is “Industrializing Intelligence: The Agentic Enterprise.” What does that mean? Consider this: Somewhere right now ...

With rapid advances in in vivo CAR‑T, gene editing, and cancer immunotherapy – alongside headline‑making acquisitions such as Eli Lilly & Orna, BMS & Orbital, AbbVie & Capstan, and BioNTech & CureVac ...

Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge. And pharma isn’t treating it like one yet.

Novo Nordisk is facing generics of its GLP-1 drug in India, Atrogi is testing a new weight loss approach, and there's new ...

As geopolitical tensions ratchet up around the world, the European Psychiatric Association (EPA) has launched an initiative ...

The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD. This ...

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in type 2 diabetes (T2D) to go with its earlier encouraging data as a weight-loss therapy. The GIP, GLP-1 and glucagon agonist ...

Recognized as the field’s most comprehensive end‑to‑end meeting, this summit brings together discovery, engineering, translational, and clinical development experts to push the boundaries of TCE ...

New draft guidance from the FDA is urging pharma companies to accelerate efforts to transition from animal testing to ...